NDLI: In vitro correction of ARSA deficiency in human skin fibroblasts from Metachromatic Leukodystrophy patients after treatment with microencapsulated recombinant cells

Please wait, while we are loading the content...

Influence of ketone bodies on oxidative stress parameters in brain of developing rats in vitro

Neuroprotective effect of N-acetylcysteine in the development of diabetic encephalopathy in streptozotocin-induced diabetes

Impaired oxidation of branched-chain amino acids in the medial thalamus of thiamine-deficient rats

Hippocampal extracellular GABA correlates with metabolism in human epilepsy

In vitro correction of ARSA deficiency in human skin fibroblasts from Metachromatic Leukodystrophy patients after treatment with microencapsulated recombinant cells

Effects of the HIV treatment drugs nevirapine and efavirenz on brain creatine kinase activity

Metabolic Brain Disease : Volume 23, Issue 3, September 2008

Metabolic Brain Disease : Volume 23, Issue 2, June 2008

Metabolic Brain Disease : Volume 23, Issue 1, March 2008

Metabolic Brain Disease : Volume 22

Metabolic Brain Disease : Volume 21

Metabolic Brain Disease : Volume 20

Metabolic Brain Disease : Volume 19

Metabolic Brain Disease : Volume 18

Metabolic Brain Disease : Volume 17

Metabolic Brain Disease : Volume 16

Metabolic Brain Disease : Volume 15

Metabolic Brain Disease : Volume 14

Metabolic Brain Disease : Volume 13

Metabolic Brain Disease : Volume 12

In vitro correction of ARSA deficiency in human skin fibroblasts from Metachromatic Leukodystrophy patients after treatment with microencapsulated recombinant cells

Content Provider	Springer Nature Link
Author	Lagranha, Valeska Lizzi Baldo, Guilherme Carvalho, Talita Giacomet Burin, Maira Saraiva Pereira, Maria Luiza Matte, Ursula Giugliani, Roberto
Copyright Year	2008
Abstract	Metachromatic leukodystrophy (MLD) is an autosomal recessive disorder due to arylsulfatase A (ARSA) deficiency that affects primarily the central nervous system. Ongoing treatments include enzyme replacement therapy and bone marrow transplantation, both limited in their effects due to the blood-brain barrier. An alternative approach would be the in situ implantation of encapsulated cells over expressing ARSA. Based on that, we tested the ability of encapsulated BHK cells over expressing ARSA to correct the enzyme deficiency in MLD patients' fibroblasts. Three groups were analyzed: fibroblasts treated with ARSA-over expressing BHK cells (rBHK) trapped in alginate capsules (capsules group), fibroblasts treated with supernatant of non-encapsulated rBHK (uptake control) and fibroblasts treated with empty capsules (empty group). Untreated and normal fibroblasts were used as controls. rBHK obtained by clone selection after non-viral transfection with pTARSA-CMV2. ARSA activity was measured after 1, 2, 3 and 4 weeks of treatment and β-gal was used as reference enzyme. Statistical analysis was performed using ANOVA and Tukey's test. Normal fibroblasts showed ARSA activity of 23.9 + /− 2.01 nmol/h/mg of protein, whereas untreated MLD fibroblasts had the low ARSA activity (2.22 + /− 0.17). In the empty group, ARSA activity was equal to that of untreated fibroblasts (2.71 + /− 0.34). Capsules and uptake control groups showed higher enzymatic activity levels, compared to MLD untreated, 23.42 + /− 6.39 and 42.35 + /− 5.20, respectively (p < 0.01 for all groups). Encapsulated rBHK clones show potential as a new therapeutic strategy for the treatment of MLD, reaching normal enzyme levels in human MLD fibroblasts.
Starting Page	469
Ending Page	484
Page Count	16
File Format	PDF
ISSN	08857490
Journal	Metabolic Brain Disease
Volume Number	23
Issue Number	4
e-ISSN	15737365
Language	English
Publisher	Springer US
Publisher Date	2008-09-17
Publisher Place	Boston
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Alginate Arylsulfatase A Cell encapsulation Gene therapy Metachromatic Leukodystrophy Oncology Biochemistry Neurology Neurosciences
Content Type	Text
Resource Type	Article
Subject	Biochemistry Neurology (clinical) Cellular and Molecular Neuroscience

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Three novel variants in the arylsulfatase A (ARSA) gene in patients with metachromatic leukodystrophy (MLD)

Case report: A compound heterozygous mutations in ARSA associated with adult-onset metachromatic leukodystrophy

Three Novel Mutant Arylsulfatase A Alleles Causing Metachromatic Leukodystrophy

Case Report: Novel Arylsulfatase A (ARSA) Gene Mutations in a Patient With Adult-Onset Metachromatic Leukodystrophy Misdiagnosed as Multiple Sclerosis

Correction to: Three novel variants in the arylsulfatase A (ARSA) gene in patients with metachromatic leukodystrophy (MLD)

An Italian Cohort Study Identifies Four New Pathologic Mutations in the ARSA Gene

Metachromatic Leukodystrophy: Diagnosis, Modeling, and Treatment Approaches

METACHROMATIC LEUKODYSTROPHY: ARYLSULFATASE-A DEFICIENCY IN SKIN FIBROBLAST CULTURES *

A patient presenting a 22q13 deletion associated with an apparently balanced translocation t(16;22): an illustrative case in the investigation of patients with low ARSA activity

In vitro correction of ARSA deficiency in human skin fibroblasts from Metachromatic Leukodystrophy patients after treatment with microencapsulated recombinant cells

Similar Documents

Three novel variants in the arylsulfatase A (ARSA) gene in patients with metachromatic leukodystrophy (MLD)

Case report: A compound heterozygous mutations in ARSA associated with adult-onset metachromatic leukodystrophy

Three Novel Mutant Arylsulfatase A Alleles Causing Metachromatic Leukodystrophy

Case Report: Novel Arylsulfatase A (ARSA) Gene Mutations in a Patient With Adult-Onset Metachromatic Leukodystrophy Misdiagnosed as Multiple Sclerosis

Correction to: Three novel variants in the arylsulfatase A (ARSA) gene in patients with metachromatic leukodystrophy (MLD)

An Italian Cohort Study Identifies Four New Pathologic Mutations in the ARSA Gene

Metachromatic Leukodystrophy: Diagnosis, Modeling, and Treatment Approaches

METACHROMATIC LEUKODYSTROPHY: ARYLSULFATASE-A DEFICIENCY IN SKIN FIBROBLAST CULTURES *

A patient presenting a 22q13 deletion associated with an apparently balanced translocation t(16;22): an illustrative case in the investigation of patients with low ARSA activity

In vitro correction of ARSA deficiency in human skin fibroblasts from Metachromatic Leukodystrophy patients after treatment with microencapsulated recombinant cells